基本面看着还挺稳的。_老虎社区_美港股上老虎

基本面看着还挺稳的。虽然公司这几年还在亏钱，但手里有张王牌——核心产品达伯特。这可是国内首个、全球第三个获批的KRAS G12C抑制剂，2024年8月就拿到了中国商业化许可，这个赛道潜力可不小。$劲方医药-B(02595)$

$劲方医药-B (02595.HK)$ 孖展超购逾2269倍，基石投资者认购总额已达1亿美元，也创2022年以来港股 18A 生物科技公司新高。【劲方暗盘大涨超100%后，今日首日上市高开大涨。大家还拿着吗？创新药龙头，接下来你是否还继续看好？】

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":479658396209304,"tweetId":"479658396209304","gmtCreate":1758114373801,"gmtModify":1758114376429,"author":{"id":10000000000010488,"idStr":"10000000000010488","authorId":10000000000010488,"authorIdStr":"10000000000010488","name":"欲山行","avatar":"https://static.tigerbbs.com/e460befb8b73628d17452d4795753dfd","vip":8,"userType":8,"introduction":".","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":145,"starInvestorFlag":false},"themes":[{"themeId":"541eb458f98047db8a507cdc45f7234d","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"劲方医药-B首日大涨！继续持有or止盈？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":541eb458f98047db8a507cdc45f7234d}&rnconfig={\"headerBarHidden\": true}","description":"$劲方医药-B (02595.HK)$ 孖展超购逾2269倍，基石投资者认购总额已达1亿美元，也创2022年以来港股 18A 生物科技公司新高。【劲方暗盘大涨超100%后，今日首日上市高开大涨。大家还拿着吗？创新药龙头，接下来你是否还继续看好？】","image":"https://static.tigerbbs.com/5130bac90455668eaf93529d3ce74155"}],"images":[],"coverImages":[],"html":"<html><head></head><body><p> 基本面看着还挺稳的。虽然公司这几年还在亏钱，但手里有张王牌——核心产品达伯特。这可是国内首个、全球第三个获批的KRAS G12C抑制剂，2024年8月就拿到了中国商业化许可，这个赛道潜力可不小。<a data-mention-id=\"02595\" class=\"teditor-mention\" data-mention-name=\"劲方医药-B\" href=\"https://laohu8.com/S/02595\">$劲方医药-B(02595)$</a> </p></body></html>","htmlText":"<html><head></head><body><p> 基本面看着还挺稳的。虽然公司这几年还在亏钱，但手里有张王牌——核心产品达伯特。这可是国内首个、全球第三个获批的KRAS G12C抑制剂，2024年8月就拿到了中国商业化许可，这个赛道潜力可不小。<a data-mention-id=\"02595\" class=\"teditor-mention\" data-mention-name=\"劲方医药-B\" href=\"https://laohu8.com/S/02595\">$劲方医药-B(02595)$</a> </p></body></html>","text":"基本面看着还挺稳的。虽然公司这几年还在亏钱，但手里有张王牌——核心产品达伯特。这可是国内首个、全球第三个获批的KRAS G12C抑制剂，2024年8月就拿到了中国商业化许可，这个赛道潜力可不小。$劲方医药-B(02595)$","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/479658396209304","repostId":0,"isVote":1,"tweetType":1,"viewCount":1416,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02595"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":true,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":189,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/479658396209304"}